Whooping Cough Vaccine Study
The study will look at the safety of the investigational vaccine and also compare how well it works with the currently recommended whooping cough vaccine.
The Children’s Hospital at Westmead is taking part in a clinical research study looking at a potential new vaccine that aims to protect against whooping cough infection (pertussis).
Whooping cough disease is caused by bacteria called Bordetella pertussis. Whooping cough is a severe respiratory tract infection that kills almost 200,000 children every year worldwide. The number of infections is increasing around the world, especially in adolescents and adults, and this is thought to be due to waning immunity from the current pertussis vaccines.
How the trial works
We are doing this study to see if a single dose of the investigational product has longer-lasting immunity from pertussis than a currently licensed vaccine called Boostrix.
You or your child may be eligible to participate if you/they:
- Are aged between 10 and 17 years inclusive;
- Are in generally good health; and
- Have received two or more doses of an acellular pertussis vaccine in the past
Participants in the study will be required to attend up to four visits and respond to up to one follow-up phone call for a total study duration of about 16 weeks (home visits may be possible).
Participants will be reimbursed for your travel/time costs incurred.
Like to join?
If you are interested in joining or would like more information, please contact the Research Team on 0429 849 440 or via email.
This project has been approved by the Sydney Children’s Hospitals Network Human Research Ethics Committee. If you have any concerns about the conduct of this study, please contact the Executive Officer at the Ethics Committee 02 9845 1253 and quote approval number 2020/ETH02847.